进入财报季，各个公司逐渐交出了2025年的业绩答卷。 2月26日，AI制药的两大头部玩家——薛定谔（Schrödinger）和“英伟达概念股”Recursion罕见地在同一天发布财报。

REC-994是Recursion立项最早的项目之一，一度也是进度最靠前的临床管线，并且在Ⅱ期研究中，展现出病灶缩小、功能改善的积极信号，但在后续的长期扩展研究中，这种疗效未能维持，转换剂量组也没有积极趋势。

加利福尼亚州门洛帕克 - PacBio (NASDAQ:PACB)今日发布新闻稿宣布,任命Christopher Gibson博士加入其董事会。 Gibson是临床阶段生物技术公司Recursion (NASDAQ:RXRX)的联合创始人兼董事会主席。在Recursion,他领导开发了一个将生物数据生成与机器学习相结合的药物发现平台。他带领公司完成了募集资金、战略合作伙伴关系建立以及公开上市。 P ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Recursion Pharmaceuticals(纳斯达克股票代码:RXRX)于2026年2月25日公布了2025年第四季度及全年业绩,展示了其AI驱动药物发现平台的首次临床验证以及显著的财务纪律。该公司公布的业绩好于预期,2025年第四季度每股收益为-$0.21,超出预期的-$0.30,营收为$35.54百万,超出预期45%。该股在盘前交易中飙升11%至$3.92,反映出投资者对公司临床和运营 ...

RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA talks.

Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.

Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...

Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results. Read more here.

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company. The new company will continue using the ...

Recursion Pharmaceuticals (NASDAQ:RXRX) used its latest earnings call to emphasize what management described as an inflection ...